MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/hae.14709

Медицинская библиотека · Haemophilia : the official journal of the World Federation of Hemophilia · 2022

Laying the foundations for gene therapy in Italy for patients with haemophilia A: A Delphi consensus study.

Castaman Giancarlo, Carulli Christian, De Cristofaro Raimondo, Follino Marco, Lupi Angelo, Mancuso Maria Elisa, Mansueto Maria Francesca, Molinari Angelo Claudio, Pasquetti Pietro, Santoro Cristina, Santoro Rita Carlotta, Siragusa Sergio, Solimeno Luigi Piero, Tripodi Armando, Zanon Ezio, Minno Giovanni Di

СтатьяОбзорConsensus StatementПеревод пока не подготовлен

Аннотация

INTRODUCTION

Current treatment for haemophilia A involves factor VIII replacement or non-replacement (emicizumab) therapies, neither of which permanently normalise factor VIII levels. Gene therapy using adeno-associated viral (AAV) vectors is an emerging long-term treatment strategy for people with severe haemophilia A (PwSHA) that is likely to be available for clinical use in the near future.

AIM: This article proposes practical guidelines for the assessment, treatment, and follow-up of potential PwSHA candidates for AAV-based gene therapy.

METHOD: Using the Delphi method, a working group of Italian stakeholders with expertise in and knowledge of the care of adults with haemophilia A analysed literature for AAV-based gene therapy and drafted a list of statements that were circulated to a panel of Italian peers. During two rounds of voting, panel members voted on their agreement with each statement to reach a consensus.

RESULTS

The Delphi process yielded 40 statements regarding haemophilia A gene therapy, across five topics: (1) organisational model; (2) multidisciplinary team; (3) patient engagement; (4) laboratory surveillance; and (5) patient follow-up and gene therapy outcomes. The consensus was reached for all 40 statements, with the second round of voting needed for five statements.

CONCLUSION

Use of the hub-and-spoke organisational model and multidisciplinary teams are expected to optimise patient selection for gene therapy, as well as the management of dosing and patient follow-up, patient engagement, laboratory surveillance, and patient expectations regarding outcomes. This approach should allow the benefits of AAV-based gene therapy for haemophilia A to be maximised.

Для цитирования: Castaman Giancarlo, Carulli Christian, De Cristofaro Raimondo, Follino Marco, Lupi Angelo, Mancuso Maria Elisa, Mansueto Maria Francesca, Molinari Angelo Claudio, Pasquetti Pietro, Santoro Cristina, Santoro Rita Carlotta, Siragusa Sergio, Solimeno Luigi Piero, Tripodi Armando, Zanon Ezio, Minno Giovanni Di. Laying the foundations for gene therapy in Italy for patients with haemophilia A: A Delphi consensus study.. Haemophilia : the official journal of the World Federation of Hemophilia. 2022. DOI: 10.1111/hae.14709.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.